DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 5,990,159 Meulemans Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 5,990,159 Meulemans Et Al USOO5990159A United States Patent (19) 11 Patent Number: 5,990,159 Meulemans et al. (45) Date of Patent: Nov. 23, 1999 54 USE OF 5HT4 RECEPTOR ANTAGONISTS WO FOR OVERCOMING GASTRONTESTINAL 94.00113A 1/1994 WIPO. EFFECTS OF SEROTONIN REUPTAKE WO INHIBITORS 9408998A 4/1994 WIPO. WO 75 Inventors: Ann Louise Gabrielle Meulemans, 9427987A 12/1994 WIPO. Mol; Jean-Paul René Marie WO André Bosmans, Rijkevorsel, both of 9504737A 2/1995 WIPO. Belgium 73 Assignee: Janssen Pharmaceutica, N.V., Beerse, OTHER PUBLICATIONS Belgium Chemical Abstracts, vol. 122, No. 15, Apr. 10, 1995, 21 Appl. No.: 09/117,974 Abstract No. 178309, A. Lucchelli et al.: “The interaction of 22 PCT Filed: Feb. 7, 1997 antidepressant drugs with central and peripherical enteric 5-HT3 and 5-HT4 receptors”. 86 PCT No.: PCT/EP97/00586 S371 Date: Aug. 11, 1998 Primary Examiner Raymond Henley, III S 102(e) Date: Aug. 11, 1998 Attorney, Agent, or Firm-Ellen Ciambrone Coletti 87 PCT Pub. No.: WO97/29739 57 ABSTRACT PCT Pub. Date: Aug. 21, 1997 The present invention concerns the use of receptor antago 30 Foreign Application Priority Data nists of the 5HT4 receptor for avoiding, alleviating, Sup Feb. 15, 1996 EP European Pat. Off. .............. 962OO38O pressing or overcoming the gastrointestinal Side-effects of Serotonin reuptake inhibitors. The present invention also 51 Int. CI. A61K 31/34; A61K 31/135 concerns pharmaceutical formulations comprising 5HT4 52 U.S. Cl. ............................................. 514/469; 514/651 receptor antagonists for alleviating, Suppressing or overcom 58 Field of Search ...................................... 514/469, 651 ing the gastrointestinal Side-effects of Serotonin reuptake inhibitors, as well as pharmaceutical compositions compris 56) References Cited ing 5HT4 receptor antagonists and Serotonin reuptake FOREIGN PATENT DOCUMENTS inhibitors. WO 92001.03A 1/1992 WIPO. 11 Claims, 8 Drawing Sheets U.S. Patent Nov. 23, 1999 Sheet 1 of 8 5,990,159 Uuuu6H Z| ||0 8 ?InsSºud 00|| OOZ 008 007 00C 009 ueÐUu‘W’E’SF U.S. Patent Nov. 23, 1999 Sheet 2 of 8 5,990,159 Uuuu6H |Z ||0 8 eunssºud 00|| 00Z 009 009 009 ueÐUu‘W’E’SF U.S. Patent Nov. 23, 1999 Sheet 3 of 8 5,990,159 Uuuu6H Juaan?!g Z| 8 ?unssºud 00|| 00Z 009 007 009 009 ueÐUu‘W’E’SF U.S. Patent Nov. 23, 1999 Sheet 4 of 8 5,990,159 J???e 00|| OOZ 007 009 ueÐUuF‘W’E’S U.S. Patent Nov. 23, 1999 Sheet 5 of 8 5,990,159 Uuuu6H eunssºud 00|| 00Z 007 009 ueÐUu‘W’E’SF U.S. Patent Nov. 23, 1999 Sheet 6 of 8 5,990,159 // 8 eunssºud 00Z 00€ 009 009 U.S. Patent Nov. 23, 1999 Sheet 7 of 8 5,990,159 ?unssºuduuuu)(6H 00|| OOZ 009 BÐUuu‘W’E’SF U.S. Patent Nov. 23, 1999 Sheet 8 of 8 5,990,159 aan?!Jg ?unsselduuuu)(6H ueÐUu‘W’E’SF 5,990,159 1 2 USE OF 5HT4 RECEPTOR ANTAGONSTS exerting a regulated tonic contraction (gastric tone), accom FOR OVERCOMING GASTRONTESTINAL plishes the reservoir function of the Stomach, namely gastric EFFECTS OF SEROTONN REUPTAKE accommodation and emptying. Impairment of adaptive INHIBITORS relaxation as a response to food intake may be the patho physiological basis of Some gastrointestinal disturbances or This application is the national Stage of application no. disorders associated with the use of SSRIs. PCT/EP97/00586, filed Feb. 7, 1997, which application Patients Suffering from dyspepsia after the intake of claims priority from EP 96.200.380.2, filed Feb. 15, 1996. SSRIs feel hungry but cannot finish a normal meal. This is The present invention concerns the use of antagonists of explained by this diminished Stomach compliance. Normally the 5HT4 receptor for avoiding, alleviating, Suppressing or when a Subject Starts eating, the Stomach will show an overcoming the gastrointestinal side-effects of (Selective) adaptive relaxation, i.e. the Stomach will relax to accept the Serotonin reuptake inhibitors. The present invention also food that is ingested. This adaptive relaxation is not possible concerns pharmaceutical formulations comprising 5HT4 when the Stomach compliance is hampered. receptor antagonists and Serotonin reuptake inhibitors for The problem to be solved is to provide a means for avoiding, alleviating, Suppressing or Overcoming the gas 15 avoiding, alleviating, Suppressing or overcoming the gas trointestinal Side-effects of Serotonin reuptake inhibitors. trointestinal disturbances which are associated with the Depression in its many variations has recently become intake of SSRIs, i.e. to normalize the compliance of the much more visible to the general public than it has previ Stomach by reducing the gastric tone to a normal level. ously been. It is now recognized as an extremely damaging Unexpectedly, we have found that 5HT4 receptor antago disorder, and one that afflicts a Surprisingly large fraction of nists can normalise the diminished Stomach compliance the population. Suicide is the most extreme Symptom of caused by the administration of SSRIs, thus avoiding, depression, but many people, not So drastically afflicted, live alleviating, Suppressing or overcoming the gastrointestinal in misery and partial or complete uselessness, which may disturbances caused by the administration of SSRIs. It also afflict their family. should be noted that the 5HT4 receptor antagonists do not as Depression is often associated with other diseases or 25 Such influence the Stomach compliance, they only Seem to conditions, or caused by Such other conditions. For example, antagonise the effect on the stomach caused by the SSRIs. it is associated with Parkinson's disease; with HIV infection; Hence, there is provided the use of a 5HT4 receptor with Alzheimer disease; and with abuse of anabolic Steroids. antagonist for the manufacture of a medicament to avoid, Depression may also be associated with abuse of any alleviate, SuppreSS or overcome the gastrointestinal distur Substance, or may be associated with behavioral problems bances caused by SSRIs. Also provided is a method of resulting from or occuring in combination with head avoiding, alleviating, Suppressing or overcoming the gas injuries, mental retardation or stroke (EP 0714663). trointestinal disturbances of SSRIs. During the last two decades, the treatment of depression The term "selective Serotonin reuptake inhibitors' as with antidepressants has moved from the treatment of hoS used herein refer to compounds that selectively inhibit the pitalised melancholic inpatients to the outpatient Setting. 35 (re-)uptake of Serotonin. Relevant tests to determine whether During the last few years, the majority of depressed patients, a compound is a Selective Serotonin reuptake inhibitor are including patients with moderate or mild depressive known in the art (for an overview see Life Sciences, 57, Symptoms, are now treated in primary care. Recent Studies 411–441,1995). have shown that mild depression is a Serious condition, The term “selective serotonin reuptake inhibitors” or representing Social and economical liability to the patient 40 “SSRIs' will both be used hereinunder. The terms refer to and a high cost to Society. Such patient clearly benefits from the compounds as Such or where appropriate to the phar therapy with antidepressants. One of the main contributing maceutically acceptable acid or base addition Salts thereof factors to this evolution in therapeutic practice has been the or, again where appropriate, to Stereochemically isomeric introduction of new antidepressants, among which the Selec forms thereof. tive serotonin reuptake inhibitors (SSRIs) are the most 45 The term “5HT4 receptor antagonist” refers to the com important and most widely prescribed. Although the SSRIs pounds as Such or where appropriate to the pharmaceutically are Said to have a lesser incidence of Side effects, Still the use acceptable acid or base addition Salt thereof or, again of SSRIs is hampered by a number of adverse effects. The appropriate, to Stereochemically isomeric forms thereof. adverse effects occurring most frequently during treatment The pharmaceutically acceptable acid addition Salts as with SSRIs are gastrointestinal disturbances, Such as, for 50 mentioned hereinabove are meant to comprise the therapeu example nausea, diarrhoea/loose Stools, constipation, with tically active non-toxic acid addition Salt forms which the an incidence of 6 to 37% (Drugs 43 (Suppl. 2), 1992). compounds are able to form. The compounds which have Nausea is the main adverse effect in terms of incidence. basic properties can be converted in their pharmaceutically These adverse effects, although mild to moderate in Severity, acceptable acid addition Salts by treating Said base form with shy some patients away from treatment with SSRIs. The 55 an appropriate acid. Appropriate acids comprise, for percentage of patients withdrawing because of nausea example, inorganic acids Such as hydrohalic acids, e.g. ranges from 3 to 8% of the patients. Moreover it has been hydrochloric or hydrobromic acid, Sulfuric, nitric, phospho frequently observed that after administration of SSRIs, ric and the like acids, or organic acids Such as, for example, patients Suffer from dyspepsia. acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, We discovered that the gastrointestinal disturbances 60 malonic, Succinic (i.e. butanedioic acid), maleic, fumaric, associated with the administration of SSRIs is mainly due to malic, tartaric, citric, methaneSulfonic, ethaneSulfonic, a diminished compliance of the Stomach. The “compliance benzeneSulfonic, p-toluenesulfonic, cyclamic, Salicylic, of the Stomach” can be expressed as the ratio of the Volume p-aminoSalicylic, pamoic and the like acids. of the Stomach over the pressure exerted by the Stomach The pharmaceutically acceptable addition Salts as men wall. The compliance of the Stomach relates to the gastric 65 tioned hereinabove are meant to comprise the therapeuti tone, which is the result of the tonic contraction of muscle cally active non-toxic base addition Salt forms which the fibers of the proximal Stomach. This proximal part, by compounds are able to form. Examples of Such base addition 5,990,159 3 4 Salt forms are, for example, the Sodium, potassium, calcium LY-353433 (Eli Lilly Co Ltd) (J.
Load more

Recommended publications
  • 付表 ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated
    付表ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated Pharmaceutical Active Ingredients 号(Sub-heading) 品名 Description 2818.30 アルゲルドラート algeldrate 2833.22 アルスルフ alusulf 2842.10 アルマシラート almasilate 2842.10 シマルドラート simaldrate 2842.90 硫酸アルマドラ ート almadrate sulfate 2842.90 アルマガート almagate 2842.90 カルバルドラード carbaldrate 2842.90 ヒドロタルシト hydrotalcite 2842.90 マガルドラート magaldrate 2843.30 オーラノフィン auranofin 2843.30 金チオグリカニド aurothioglycanide 2843.30 金チオりんご酸ナトリウム sodium aurothiomalate 2843.30 金チオ硫酸ナトリウム sodium aurotiosulfate 2843.90 カルボプラチン carboplatin 2843.90 シスプラチン cisplatin 2843.90 デキソルマプラチン dexormaplatin 2843.90 エンロプラチン enloplatin 2843.90 イプロプラチン iproplatin 2843.90 ロバプラチン lobaplatin 2843.90 ミボプラチン miboplatin 2843.90 ネダプラチン nedaplatin 2843.90 オルマプラチン ormaplatin 2843.90 オキサリプラチン oxaliplatin 2843.90 セブリプラチン sebriplatin 2843.90 スピロプラチン spiroplatin 2843.90 ゼニプラチン zeniplatin 2844.40 アルツモマブ altumomab 2844.40 塩化セシウム(131Cs) cesium (131 Cs) chloride 2844.40 クロルメロドリン(197Hg) chlormerodrin (197 Hg) 2844.40 シアノコバラミン(57Co) cyanocobalamin (57 Co) 2844.40 シアノコバラミン(58Co) cyanocobalamin (58 Co) 2844.40 シアノコバラミン(60Co) cyanocobalamin (60 Co) 2844.40 エチオダイズド油(131I) ethiodized oil (131 I) 2844.40 くえん酸第二鉄(59Fe)注射液 ferric (59 Fe) citrate in 2844.40 フィブリノゲン(125I) fibrinogen (125 I) 2844.40 フルデオキシグルコー ス(18F) fludeoxyglucose ( 18 F) 2844.40 フルオロドパ(18F) fluorodopa (18 F) 2844.40 くえん酸ガリウム(67Ga) gallium (67 Ga) citrate 2844.40 金コロイド(198Au) gold (198 Au), colloidal 2844.40 イオベングアン(131I) iobenguane (131 I) 2844.40 よう化人血清アルブミン(125I) iodinated (125 I) human serum albumin 2844.40 よう化人血清アルブミン(131I) iodinated
    [Show full text]
  • In Vivo Electrophysiological Recordings of the Effects of Antidepressant Drugs
    Experimental Brain Research (2019) 237:1593–1614 https://doi.org/10.1007/s00221-019-05556-5 REVIEW In vivo electrophysiological recordings of the efects of antidepressant drugs Paul J. Fitzgerald1 · Brendon O. Watson1 Received: 9 October 2018 / Accepted: 6 May 2019 / Published online: 11 May 2019 © The Author(s) 2019 Abstract Antidepressant drugs are a standard biological treatment for various neuropsychiatric disorders, yet relatively little is known about their electrophysiologic and synaptic efects on mood systems that set moment-to-moment emotional tone. In vivo electrical recording of local feld potentials (LFPs) and single neuron spiking has been crucial for elucidating important details of neural processing and control in many other systems, and yet electrical approaches have not been broadly applied to the actions of antidepressants on mood-related circuits. Here we review the literature encompassing electrophysiologic efects of antidepressants in animals, including studies that examine older drugs, and extending to more recently synthesized novel compounds, as well as rapidly acting antidepressants. The existing studies on neuromodulator-based drugs have focused on recording in the brainstem nuclei, with much less known about their efects on prefrontal or sensory cortex. Studies on neuromodulatory drugs have moreover focused on single unit fring patterns with less emphasis on LFPs, whereas the rapidly acting antidepressant literature shows the opposite trend. In a synthesis of this information, we hypothesize that all classes of antidepressants could have common fnal efects on limbic circuitry. Whereas NMDA receptor blockade may induce a high powered gamma oscillatory state via direct and fast alteration of glutamatergic systems in mood-related circuits, neuromodulatory antidepressants may induce similar efects over slower timescales, corresponding with the timecourse of response in patients, while resetting synaptic excitatory versus inhibitory signaling to a normal level.
    [Show full text]
  • Low Dose Pipamperone in Treating Mood and Anxiety Disorders
    (19) & (11) EP 2 236 138 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 06.10.2010 Bulletin 2010/40 A61K 31/4545 (2006.01) A61K 45/06 (2006.01) A61P 25/22 (2006.01) A61P 25/24 (2006.01) (2006.01) (21) Application number: 09156752.9 A61K 31/343 (22) Date of filing: 30.03.2009 (84) Designated Contracting States: • van der Geest, Ronald AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 4835 AA, Breda (BE) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR (74) Representative: De Clercq, Ann G. Y. et al Designated Extension States: De Clercq & Partners cvba AL BA RS Edgard Gevaertdreef 10 a 9830 Sint-Martens-Latem (BE) (71) Applicant: PharmaNeuroBoost N.V. 3570 Alken (BE) Remarks: Claim .17-19,21-24ed to be abandoned due to non- (72) Inventors: payment of the claims fee (Rule 45(3) EPC). • Buntinx, Erik 3570, Alken (BE) (54) Low dose pipamperone in treating mood and anxiety disorders (57) The present invention relates to the use of combinations comprising pipamperone and an SSRI, SNDRI or SNRI and compositions comprising the same for the treatment of mood or anxiety disorders. EP 2 236 138 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 236 138 A1 Description Field of the invention 5 [0001] The invention relates to the field of neuropsychiatry. More specifically, the invention relates to the use of pipamperone in augmenting and in a faster onset of serotonin re- uptake inhibitors, such as SSRIs, SNDRIs and SNRIs, in treating mood and anxiety disorders.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • I (Acts Whose Publication Is Obligatory) COMMISSION
    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
    [Show full text]
  • Wo 2008/116165 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 25 September 2008 (25.09.2008) WO 2008/116165 A2 (51) International Patent Classification: MCNEIL, Laurie [US/US]; University Of North Car A61M 11/02 (2006.01) olina-Chapel Hill, Department Of Physics And Astronomy, Chapel Hill, NC (US). WETZEL, Paul [US/US]; 456 (21) International Application Number: Quail Hollow Road, Jefferson, NC 28640 (US). CRISS, PCT/US2008/057847 Ron [US/US]; P.O. Box 1598, West Jefferson, NC 28694 (US). (22) International Filing Date: 2 1 March 2008 (21.03.2008) (74) Agent: RISLEY, David, R.; Thomas, Kayden, Horste- (25) Filing Language: English meyer & Risley, LIp., 600 Galleria Parkway, Atlanta, GA 30339-5948 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, 11/689,315 21 March 2007 (2 1.03.2007) US CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, (71) Applicant (for all designated States except US): NEXT IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, SAFETY, INC. [US/US]; 1329 Phoenix Colvard Drive, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, Jefferson, NC 28640 (US). MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, (72) Inventors; and SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (75) Inventors/Applicants (for US only): LEMAHIEU, Ed¬ ZA, ZM, ZW ward [US/US]; 1120 Dean Avenue, San Jose, CA 95125 (US).
    [Show full text]
  • Antidepressant Medications and Cognitive Functioning in Major Depressive Disorder Rachel Kay Wayne State University
    Wayne State University Wayne State University Theses 1-1-2013 Antidepressant Medications And Cognitive Functioning In Major Depressive Disorder Rachel Kay Wayne State University, Follow this and additional works at: http://digitalcommons.wayne.edu/oa_theses Part of the Psychology Commons Recommended Citation Kay, Rachel, "Antidepressant Medications And Cognitive Functioning In Major Depressive Disorder" (2013). Wayne State University Theses. Paper 265. This Open Access Thesis is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Theses by an authorized administrator of DigitalCommons@WayneState. ANTIDEPRESSANT MEDICATIONS AND COGNITIVE FUNCTIONING IN MAJOR DEPRESSIVE DISORDER by RACHEL E. KAY THESIS Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of MASTER OF ARTS 2013 MAJOR: PSYCHOLOGY (Clinical) Approved by: ______________________________ Advisor Date ACKNOWLEDGMENTS I want to thank my supportive advisor, Dr. Lisa J. Rapport, for her wisdom, guidance, and support throughout the process of this thesis project. Her continued mentorship and passion for teaching have enriched the Master’s thesis experience on a personal and professional level. I also want to thank my other committee members, Drs. Scott A. Langenecker and Marla Bartoi, whose efforts contributed to my conceptualization of the project and its implications. I appreciate the additional consultation from Dr. Scott
    [Show full text]
  • Salivary Biomarkers of Stress in Psychological Patients on Fluoxetine Therapy
    UNIVERSIDAD COMPLUTENSE DE MADRID FACULTAD DE FARMACIA Departamento de Farmacología TESIS DOCTORAL Salivary Biomarkers of Stress in Psychological Patients on Fluoxetine Therapy Biomarcadores Salivales de Estrés en Pacientes Psicológicos en Tratamiento con Fluoxetina MEMORIA PARA OPTRA AL GRADO DE DOCTOR PRESENTADA POR Nuha Mohammed Yahya Al-Dallee DIRECTORAS María Teresa Ortega Hernández Agero Nahla O.M. Tawfik Madrid, 2017 UNIVERSIDAD COMPLUTENSE DE MADRID FACULTAD DE FARMACIA Departamento de Farmacología Salivary Biomarkers of Stress in Psychological Patients on Fluoxetine Therapy Biomarcadores Salivales de Estrés en Pacientes Psicológicos en Tratamiento con Fluoxetina TESIS DOCTORAL Nuha Mohammed Yahya Al-Dallee Madrid, 2017 UNIVERSIDAD COMPLUTENSE DE MADRID FACULITAD DE FARMACIA Departamento de Farmacología Dra. Dña. María Teresa Ortega Hernández-Agero, Profesora Titular, del Departamento de Farmacología de la Facultad de Farmacia de la Universidad de Complutense de Madrid y Dra. Dña. Nahla O. M. Tawfiq, Profesora Titular, de la Facultad de Medicina de la Universidad de Nineveh. CERTIFICAN: Que la presente Tesis Doctoral presentada por Dña. Nuha Mohammed Yahya AL-Dallee, Titulada “Salivary Biomarkers of Stress in Psychological Patients on Fluoxetine Therapy”, ha sido realizada bajo nuestra inmediata dirección y asesoramiento. Concluido el trabajo experimental y bibliográfico, autorizamos su presentación para sea juzgada por el Tribunal correspondiente. Madrid, Abril 2017 Dra. María Teresa Ortega Hernández-Agero Dra. Nahla O.M. Tawfiq DEDICATION *TO MY BELOVED COUNTRY IRAQ. *TO THE PEOPLE OF MOSUL CITY, MOSUL WILL RETURN BETTER. *TO MY FATHER & MOTHER. * TO MY LOVELY HUSBEND AND MY GREAT LOVE (BAZIL). TO OUR LIFE AND FUTURE “WASEEM” *TO MY SISTERS & BROTHERS. *TO MY FRIENDS. *TO ALL MEDICAL STUDENTS.
    [Show full text]
  • Antidepressant Screening Demonstrated Non-Monotonic Responses to Amitriptyline, Amoxapine and Sertraline in Locomotor Activity Assay in Larval Zebrafish
    cells Article Antidepressant Screening Demonstrated Non-Monotonic Responses to Amitriptyline, Amoxapine and Sertraline in Locomotor Activity Assay in Larval Zebrafish Michael Edbert Suryanto 1,† , Gilbert Audira 1,2,†, Boontida Uapipatanakul 3 , Akhlaq Hussain 1, Ferry Saputra 1 , Petrus Siregar 1, Kelvin H.-C. Chen 4,* and Chung-Der Hsiao 1,2,5,* 1 Department of Bioscience Technology, Chung Yuan Christian University, Chung-Li 320314, Taiwan; [email protected] (M.E.S.); [email protected] (G.A.); [email protected] (A.H.); [email protected] (F.S.); [email protected] (P.S.) 2 Department of Chemistry, Chung Yuan Christian University, Chung-Li 320314, Taiwan 3 Department of Chemistry, Faculty of Science and Technology, Rajamangala University of Technology Thanyaburi, Thanyaburi 12110, Thailand; [email protected] 4 Department of Applied Chemistry, National Pingtung University, Pingtung 900391, Taiwan 5 Center for Nanotechnology, Chung Yuan Christian University, Chung-Li 320314, Taiwan * Correspondence: [email protected] (K.H.-C.C.); [email protected] (C.-D.H.) † These authors contributed equally to this work. Abstract: Antidepressants are well-known drugs to treat depression and major depressive disorder for humans. However, the misuse and abuse of antidepressants keep increasing with several side Citation: Suryanto, M.E.; Audira, G.; effects reported. The aim of this study was to assess the potential adverse effects of 18 antidepressants Uapipatanakul, B.; Hussain, A.; by monitoring zebrafish larval locomotor activity performance based on the total distance traveled, Saputra, F.; Siregar, P.; Chen, K.H.-C.; burst movement count, and total rotation count at four dark-light intercalated phases.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,319,953 B1 Carlson Et Al
    USOO6319953B1 (12) United States Patent (10) Patent No.: US 6,319,953 B1 Carlson et al. (45) Date of Patent: *Nov. 20, 2001 (54) TREATMENT OF DEPRESSION AND WO95/08549 3/1995 (WO). ANXETY WITH FLUOXETINE AND AN WO95/18124 7/1995 (WO). NK-1 RECEPTOR ANTAGONST WO 96/O5181 2/1996 (WO). WO 96/18643 6/1996 (WO). (75) Inventors: Emma Joanne Carlson, Puckeridge; WO 96/19233 6/1996 (WO). Nadia Melanie Rupniak, Bishops WO 96/24353 8/1996 (WO). Stortford, both of (GB) WO 98/15277 4/1998 (WO). OTHER PUBLICATIONS (73) Assignee: Merck Sharp & Dohme Ltd., Aguiar, M., et al., Physiology& Behavior, 1996, 60(4) Hoddesdon (GB) 1183-1186. (*) Notice: Subject to any disclaimer, the term of this Barden, N., et al., J. Neurochem., 1983, 41, 834-840. Bristow, L., et al., Eur: J. Pharmacol., 1994, 253, 245-252. patent is extended or adjusted under 35 Brodin, E., et al., Neuropharmacology, 1987, 26(6) U.S.C. 154(b) by 0 days. 581-590. This patent is Subject to a terminal dis Brodin, E., et al., Neuropeptides, 1994, 26, 253-260. claimer. Culman, J., et al., J. Physiol. Pharmacol., 1995, 73, 885-891. Cutler, et al., J. Psychopharmacol, 1994, 8, A22, 87. (21) Appl. No.: 09/457,241 Elliott, P. J., Exp. Brain Res. UK, 1988, 73, 354-356. (22) Filed: Dec. 8, 1999 F-D-C Reports-Prescription Pharmaceuticals and Bio technology, Dec. 8, 1997, 59(49), 10. Related U.S. Application Data File, S. E., Pharm. Biochem. Behavior, 1997, 58, 3, 747-752. (60) Division of application No.
    [Show full text]